A Multicenter, Open-label, Single-arm, Phase Ib Study to Evaluate Safety and Efficacy of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Recurrent/Metastatic Head and Neck Cancers
Latest Information Update: 14 Mar 2024
At a glance
- Drugs Mitoxantrone liposomal (Primary)
- Indications Carcinoma; Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Nasopharyngeal cancer; Squamous cell cancer; Tongue cancer
- Focus Adverse reactions
- Sponsors CSPC ZhongQi Pharmaceutical Technology
- 05 Mar 2024 Status changed from recruiting to completed.
- 07 Jun 2022 Status changed from not yet recruiting to recruiting, as per Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 07 Jun 2022 preliminary Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology